Clinical Trial Update: A Study to Evaluate Safety and Tolerability of Different Doses and Efficacy of PQ912 in Subjects With MCI and Mild AD [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating safety, tolerability, and efficacy of various doses of PQ912 in individuals with mild cognitive impairment and early Alzheimer’s dise…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Cognitive Impairment

Drugs mentioned

• PQ912

Snippet

Sponsor: Vivoryon Therapeutics N.V. | Conditions: Early Alzheimers Disease, Mild Cognitive Impairment Due to AD | Phase 2 | Status: COMPLETED